NEMGENIX

nemgenix-logo

Nemgenix is an international agricultural biotechnology company developing new technologies for the control of plant parasitic nematodes and aphids. The company was founded by Sean Hird and Mike Jones in 2007 with the aim to innovate in the field of nematode and aphid control. Both nematodes and aphids are significant pests of the world’s major crops against which there is limited natural resistance. In particular, plant parasitic nematodes are devastating root pathogens causing global losse... s of US$125bn+ pa. These small thread-like worms are endemic in all soil types and reduce yields through impaired water and nutrient uptake and increased susceptibility to other root pathogens. Likewise, losses from aphids are also very high due to the physical damage they cause and their role as a vector for plant viruses and other invasive organisms. It is estimated that aphids are the primary vector for 50% of all known plant viruses. Building on the expertise and experience of Mike Jones, an internationally regarded expert in the field of plant nematology and virology, Nemgenix has focussed on the development of novel RNAi-based crop traits to confer nematode and aphid resistance. RNA interference (‘RNAi’) is an endogenous gene silencing mechanism found in plants and other organisms which can be exploited through the design of biotech traits. Nemgenix has successfully shown proof-of-concept of its utility in a range of plant species. This work has led to a number of patent filings which are now being prosecuted in all major territories. Nemgenix is currently working with several corporate partners to progress its RNAi-based nematode control traits with field trials anticipated in 2014. Nemgenix is constructing specially designed field trial plots where nematode populations can be manipulated and soil conditions modelled, to reflect field conditions in a range of key growing areas. In 2012 Nemgenix’s Crop Protection Unit was formed to undertake the development of an integrated in silico pesticide discovery platform known as ‘i-QUEST™’. This will combine with the company’s bioassay systems and field trial resources to provide a ‘screen to field’ pesticide development capability. In the case of nematodes, the use of chemical controls is often limited by environmental legislation and cost which has resulted in increased demand for new nematicides. The i-QUEST™ platform is currently being used to exploit this opportunity. Nemgenix has research and development facilities in Perth, Australia at the Western Australia State Agricultural Biotechnology Centre and also in Harpenden, UK. Nemgenix has a team of 10 full-time researchers. The company secured seed investment in 2008 from Stone Ridge Ventures, an Australian venture capital firm, and has been awarded numerous government grants.

#People #Website #More

NEMGENIX

Social Links:

Industry:
Agriculture AgTech Biotechnology Farming

Founded:
2007-01-01

Address:
Bath, Bath And North East Somerset, United Kingdom

Country:
United Kingdom

Website Url:
http://www.nemgenix.com

Total Employee:
1+

Status:
Active

Contact:
44 (0) 1225 321 742

Email Addresses:
[email protected]

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Content Delivery Network Amazon OpenResty AdBlock Acceptable Ads Bodis DNS


Founder


michael-jones_image

Michael Jones

sean-hird_image

Sean Hird

Official Site Inspections

http://www.nemgenix.com

  • Host name: 38.31.241.220
  • IP address: 38.31.241.220
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Nemgenix"

HEMGENIX® (etranacogene dezaparvovec-drlb) | Official Patient …

HEMGENIX is the first ever FDA-approved gene therapy for hemophilia B. It is a one-time infusion that offers elevated factor IX levels for years.See details»

etranacogene dezaparvovec | CDA-AMC

Sep 26, 2024 · HEMGENIX (etranacogene dezaparvovec) is indicated for treatment of adults (aged 18 years of age or older) with Hemophilia B (congenital Factor IX deficiency) who …See details»

HEMGENIX® (etranacogene dezaparvovec-drlb) | Official Website …

HEMGENIX is the first ever FDA approved gene therapy for hemophilia B. By addressing the root cause, it offers elevated FIX levels for years. Please see Important Safety Information and full …See details»

Etranacogene dezaparvovec - Wikipedia

Etranacogene dezaparvovec is indicated for the treatment of adults with hemophilia B (congenital Factor IX deficiency) who use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes. See details»

HEMGENIX | FDA - U.S. Food and Drug Administration

Jan 4, 2023 · HEMGENIX is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who: •Currently use …See details»

Health Canada Authorizes CSL's HEMGENIX® (etranacogene

Oct 26, 2023 · HEMGENIX ® is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the …See details»

The First Gene Therapy for Hemophilia B - The …

Nov 22, 2022 · HEMGENIX is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B. It uses AAV5, a non- …See details»

HEMGENIX® (etranacogene dezaparvovec) | Why Gene Therapy

HEMGENIX ®, etranacogene dezaparvovec-drlb, is a one-time gene therapy for the treatment of adults with hemophilia B who: Currently use Factor IX prophylaxis therapy, or Have current or …See details»

Pharmacy Focus Hemgenix and Beqvez Gene Therapies - HMIG

Hemgenix (approved November 22, 2022) and Beqvez (approved April 26, 2024) are indicated for adults with Hemophilia B (without inhibitors) who use prophylactic treatment and have a …See details»

Health Canada approves Hemgenix gene therapy for hemophilia B

Nov 1, 2023 · Health Canada has approved the gene therapy Hemgenix (etranacogene dezaparvovec) for treating adults with hemophilia B who rely on routine prophylactic therapies …See details»

Health Canada approves Hemgenix gene therapy for …

Ottawa, October 26, 2023 – Health Canada has authorized Hemgenix (etranacogene dezaparvovec), gene therapy for the treatment of hemophilia B. Hemgenix is indicated for the treatment of adults with hemophilia B who …See details»

CSL Behring Announces the First Patient Has Received FDA …

Jun 20, 2023 · HEMGENIX is the first and only gene therapy for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life …See details»

Hemgenix - European Medicines Agency (EMA)

Dec 16, 2022 · Hemgenix is a medicine used to treat adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of factor IX (a protein needed …See details»

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B

Feb 22, 2023 · Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding. Gene therapy for hemophilia B aims to establish …See details»

FDA approves $3.5 million treatment for hemophilia, now the …

Nov 23, 2022 · The US Food and Drug Administration on Tuesday approved Hemgenix, a new drug to treat hemophilia. Manufacturer CSL Behring set the price at $3.5 million per treatment, …See details»

Hemophilia B and gene therapy: a new chapter with etranacogene ...

Apr 9, 2024 · The US Food and Drug Administration (FDA)’s authorization of etranacogene dezaparvovec (Hemgenix) is a significant milestone, constituting not only the first FDA …See details»

Health Canada Authorizes CSL's HEMGENIX as First Gene Therapy …

HEMGENIX® is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in …See details»

$3.5M gene therapy for hemophilia gets FDA approval

WASHINGTON (AP) — U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder. The Food and …See details»

Hemophilia B and gene therapy: a new chapter with etranacogene ...

Apr 9, 2024 · The US Food and Drug Administration (FDA)'s authorization of etranacogene dezaparvovec (Hemgenix) is a significant milestone, constituting not only the first FDA …See details»

Etranacogene dezaparvovec for treating moderately severe or

Jul 24, 2024 · Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adultsSee details»